One of the things I have learned after years in regenerative medicine is that the body rarely repairs itself through a single mechanism. Healing is a coordinated biological process requiring oxygen, blood flow, functioning mitochondria, an appropriate inflammatory response, new blood vessel formation, extracellular matrix remodeling, and constant communication between cells.
This is why I have become increasingly interested in the relationship between hyperbaric oxygen therapy (HBOT) and exosomes.
At first glance, these appear to be two very different approaches. Hyperbaric oxygen changes the physiological environment in which our cells operate, while exosomes are part of the communication system between those cells. But when we look more closely at the biology, the intersection becomes fascinating. I believe it tells us something important about where regenerative medicine is going.
Why the Cellular Environment Matters
For years, much of regenerative medicine has centered around one question: What can we introduce into an injured or degenerating tissue to stimulate repair?
That question has led us to PRP, bone marrow-derived therapies, growth factors, cells, extracellular vesicles, and other biological approaches. But I believe there is another question that may ultimately prove just as important: What is the condition of the biological environment into which we are introducing those regenerative signals?
An injured tendon, arthritic joint, damaged nerve, or poorly healing tissue does not exist in isolation. It exists within a complex biological ecosystem that includes its blood supply, immune cells, mitochondria, extracellular matrix, oxygen availability, and an enormous network of signaling molecules.
Injured and chronically dysfunctional tissues frequently have some combination of impaired circulation, inflammation, oxidative stress, mitochondrial dysfunction, and inadequate oxygenation. These processes can reinforce one another.
Poor oxygenation impairs cellular energy production. Tissue dysfunction can perpetuate inflammation, while inflammation and swelling can further compromise microcirculation. It can become a biological cycle that is difficult to interrupt.
This is where hyperbaric oxygen becomes particularly interesting.
Hyperbaric Oxygen: More Than Oxygen Delivery
Most people understand the basic concept of HBOT: a patient enters a pressurized chamber and breathes oxygen.
What happens physiologically, however, is considerably more sophisticated than simply “getting more oxygen.”
Under normal conditions, most oxygen in our blood is carried by hemoglobin inside red blood cells. Under hyperbaric conditions, increased atmospheric pressure allows substantially more oxygen to dissolve directly into the plasma, creating a much greater oxygen gradient between the circulation and the tissues.
But oxygen delivery is only part of the story.
Oxygen is not only fuel. It is also a biological signal.
Changes in oxygen availability influence pathways involved in inflammation, angiogenesis, oxidative stress, collagen production, mitochondrial activity, cellular survival, and tissue remodeling.
I therefore think of hyperbaric oxygen not simply as an oxygen-delivery treatment, but as a way of influencing the cellular microenvironment.
Mobilizing the Body’s Own Repair Cells
There is another effect of HBOT that I believe deserves much more attention in regenerative medicine: the mobilization of stem and progenitor cells from the bone marrow.
Human research has demonstrated that HBOT can increase circulating CD34+ stem/progenitor cells. In one landmark study, a single hyperbaric oxygen exposure doubled circulating CD34+ cells, while a course of 20 treatments was associated with an eightfold increase. The mechanism appears to involve nitric oxide signaling within the bone marrow, helping mobilize these cells into the circulation. This gives us another way to think about HBOT. We are not simply delivering oxygen to compromised tissue. We may also be recruiting components of the body’s own repair system.
That becomes particularly interesting when we consider how stem and progenitor cells actually exert many of their biological effects.
Exosomes and the Language of Cellular Communication
Our cells are constantly communicating, and one way they do this is through extracellular vesicles, including small extracellular vesicles commonly referred to as exosomes.
Exosomes are microscopic membrane-bound particles released by cells. They carry proteins, lipids, messenger molecules, and regulatory genetic material such as microRNAs.
I sometimes describe them as biological delivery packages: the membrane is the package, while the molecular cargo inside is the message.
When these vesicles interact with another cell, their cargo can influence how that cell behaves. This signaling can affect inflammation, immune-cell activity, angiogenesis, fibrosis, and tissue remodeling.
This has also changed the way we think about stem cells themselves. Years ago, much of the discussion centered on stem cells entering damaged tissue and transforming into whatever cells were needed.
We now understand that an important component of stem and progenitor cell biology involves paracrine signaling, the biological messages cells release into their surrounding environment. Extracellular vesicles are an important part of that communication.
Where HBOT and Exosome Biology Intersect
Now put these concepts together.
HBOT can change the biological environment. It can also mobilize bone marrow-derived stem/progenitor cells into the circulation. Exosomes and other extracellular vesicles are part of the signaling network through which cells communicate and potentially influence repair. HBOT influences the terrain. Stem/progenitor-cell mobilization may recruit additional participants. Exosomes help carry the biological instructions.
A 2025 review published in Frontiers in Bioengineering and Biotechnology examined this interaction and brought together a growing body of research on the potential relationship between HBOT and exosomes.
The intriguing question is whether improving oxygenation, vascular signaling, mitochondrial function, and the inflammatory environment creates better conditions for regenerative signaling, and whether HBOT can simultaneously influence the body’s own extracellular-vesicle response.
The emerging science suggests that it may.
Oxygen as a Biological Signal
One of the most fascinating concepts in hyperbaric medicine is the hyperoxia-hypoxia paradox.
During HBOT, tissues experience a substantial increase in oxygen availability. After treatment, oxygen levels return toward baseline. With repeated exposures, these fluctuations appear capable of activating some cellular pathways normally associated with hypoxia, despite the absence of prolonged oxygen deprivation.
One important pathway involves hypoxia-inducible factor-1 alpha, or HIF-1α.
HIF-1α is a transcription factor involved in angiogenesis, metabolism, adaptation to cellular stress, and tissue repair.
The molecular biology is complex, but the larger concept is important: changes in oxygen availability can themselves act as biological signals.
This becomes even more interesting when we return to extracellular vesicles. Research suggests that HBOT can influence circulating extracellular vesicles and alter aspects of their molecular cargo.
In other words, we may be influencing not only the environment in which cells operate, but also some of the messages those cells send to one another.
Intermittent Hypoxia and Adaptive Signaling
This concept is particularly relevant to what we do at PUR-FORM because we approach oxygen physiology from both directions. In addition to hyperbaric oxygen, we use carefully controlled intermittent hypoxia training, in which the body is exposed to brief periods of reduced oxygen followed by recovery. Intermittent hypoxia and hyperbaric oxygen are obviously not the same therapy, but they illustrate an important biological principle: cells respond not only to the amount of oxygen available, but also to changes in oxygen availability.
Carefully controlled oxygen fluctuations can engage oxygen-sensing pathways, including HIF signaling, that are involved in metabolic and vascular adaptation.
The dose and context matter enormously. Controlled, transient hypoxia is very different from chronic pathological hypoxia. But understanding how cells respond to these changing oxygen signals opens another avenue for influencing the regenerative environment.
This is one reason I find the convergence of oxygen physiology, stem/progenitor-cell mobilization, mitochondrial biology, and extracellular-vesicle signaling so compelling.
Rather than looking at each mechanism in isolation, we can begin to see a network of interacting repair systems.
How We Think About This at PUR-FORM
This concept of the cellular microenvironment is central to how we approach regenerative medicine at PUR-FORM.
We use hyperbaric oxygen because oxygen physiology matters. We use intermittent hypoxia because oxygen-sensing and adaptive pathways matter. We use PhotoBioModulation because light can influence mitochondrial function and cellular signaling. And we use physician-directed regenerative interventions because biological signaling matters.
The purpose is not to stack therapies and assume that more is better.
I am much less interested in how many tools we have than in how intelligently we use them. What interests me is sequencing. When should we improve oxygenation
and microcirculation? When should we engage adaptive oxygen-sensing pathways? When should we support mitochondrial function? When should regenerative signals be introduced? And should that sequence change depending on the patient, the tissue, and the stage of healing?
I think of this as Regenerative Medicine 2.0. The first generation focused heavily on the regenerative product: What are we putting into the patient? The next generation will increasingly ask: What is happening in the patient before, during, and after we introduce that regenerative signal?
The Future Is Not More. It Is More Precise.
I believe the future of regenerative medicine will be about selecting the right patient, identifying the right biological target, choosing the appropriate intervention and dose, determining the right sequence, and creating the right biological environment.
This is what makes the relationship between hyperbaric oxygen and exosomes so compelling. It isn’t simply about combining two treatments. It represents a different way of thinking about regeneration.
Cells need energy. Tissues need oxygen and circulation. Mitochondria need to function. Inflammation needs to be appropriately regulated. New blood vessels need to form. Stem and progenitor cells need to be recruited.
And throughout all of this, cells need to communicate with one another.
The science examining HBOT and exosomes together is still evolving, and many important questions remain regarding dosing, timing, sequencing, and patient selection.
But the biological signals are compelling enough that I believe we are beginning to see the framework for a more sophisticated approach to regenerative medicine, one built around the interaction between the therapy, the patient, and the cellular environment.
Perhaps the most important lesson has nothing to do with any individual treatment. It is a philosophy of regenerative medicine that I believe will become increasingly important: Don’t simply ask how we can make the body heal. Ask what the body needs to heal, and then create the best possible conditions for it to do what it already knows how to do.
Dr. P
